NAME

Ø

PTO

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No. First Inventor		1530.0180002/EKS/EJH	T
		Marston Manthorpe	
Title	Composition Polynucleot	ons and Methods for in vivo Delivery of otide-Based Therapeutics	

Express Mail Label No.

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	Assistant Commissioner for Patents Box Patent Application Washington, DC 20231						
1.	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee) 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. Two (2) Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other: Authorization under 37 C.F.R. § 1.136(a)(3) The name of the assignee is: Vical Incorporated						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) Prior application information: Examiner Group/Art Unit:							
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only relied upon when a portion has been inadvertently omitted from the submitted application parts.							
19. CORRESPONDENCE ADDRESS							
Customer Number or Bar Code Label	or Correspondence address below						
Customer No. 26111 (Insert Customer No. or A	Attach bar code label here)						

ADDRESS				
CITY		STATE	ZIP COD	E
COUNTRY		TELEPHONE	FAX	
NAME (Print/Type)	Elizabeth J. Haanes, Ph.D.	_//	Registration No. (Attorney/Agent)	Elizabeth J. Haanes, Ph.D.
SIGNATURE	7/10/10/20	Xloren T		Data (0 0 0 0 = = = =)

Burden Hour Statement: this form's estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

SKGF Rev 3/29/01 mac

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Attorneys at Law



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W. . WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 . FACSIMILE: (202) 371-2540 . www.skgf.com

ROBERT GREENE STERNE EDWARD J. KESSLER JORGE A. GOLDSTEIN SAMUEL L. FOX*** DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE MICHAEL Q. LEE STEVEN R. LUDWIG JOHN M. COVERT*
LINDA E. ALCORN
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN

PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER
JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE

GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
ALBERT J. FASULO II*
W. BRIAN EDGE*
ELDORA ELLISON FLOYD*
W. RUSSELL SWINDELL
THOMAS C. FIALA
LONNY L. MULLER*
BRIAN J. DEL BUONO*
VIRGIL L. BEASTON*
RYAN J. STAMPER*

KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
ANDREA J. KAMAGE**
NANCY J. LEITH**
ELIZABETH J. HAANES**
MARK P. TERRY**

*BAR OTHER THAN D.C.

**REGISTERED PATENT AGENT

***SENIOR COUNSEL

April 23, 2001

WRITER'S DIRECT NUMBER: (202) 218-7834 INTERNET ADDRESS: BHAANES@SKGF.COM

Commissioner for Patents Washington, D.C. 20231

Box Patent Application

Re:

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. To be assigned; Filed: Herewith

For: Compositions and Methods for in vivo Delivery

of Polynucleotide-Based Therapeutics

Inventors:

Manthorpe et al.

Our Ref:

1530.0180002/EKS/EJH

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. USPTO Utility Patent Application Transmittal Form PTO/SB/05;
- 2. U.S. Utility Patent Application entitled:

Compositions and Methods for *in vivo* Delivery of Polynucleotide-Based Therapeutics

and naming as inventors:

Marston MANTHORPE Jukka HARTIKKA Loretta SUKHU

the application comprising:

Commissioner for Patents April 23, 2001 Page 2

- a. specification containing:
 - i. <u>114</u> pages of description prior to the claims;
 - ii. 29 pages of claims (163 claims);
 - iii. a one (1) page abstract;
- b. <u>29</u> sheets of informal drawings: (Figures <u>1</u>, <u>2A</u>, <u>2B</u>, <u>2C-2D</u>, <u>3</u>, <u>4</u>, <u>5</u>, <u>6A-6F</u>, <u>7A-7B</u>, <u>8</u>, <u>9A-9B</u>, <u>10</u>, <u>11</u>, <u>12</u>, <u>13</u>, <u>14</u>, <u>15</u>, <u>16A-16C</u>, <u>16D</u>, <u>17A-17B</u>, <u>18</u>, <u>19A-19B</u>, <u>20A-20B</u>, <u>21</u>, <u>22</u>, <u>23</u>, <u>24</u>, <u>25</u>, and <u>26</u>); and
- c. an Application Data Sheet (37 C.F.R. § 1.76).
- 3. 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating An Extension of Time (in duplicate); and
- 4. Two (2) return postcards.

The name of the assignee is: Vical Incorporated.

Correspondence should be sent to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Elizabeth J. Haanes, Ph.D.

Agent for Applicants Registration No. 42,613

EJH/pcd Encls.